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Vinorelbine is a semi-synthetic vinca-alkaloid with a broad spec-
trum of anti-tumour activity. The vinca-alkaloids are categorized as
spindle poisons, and their mechanism of action is to interfere with
the polymerization of tubulin, a protein responsible for building the
microtubule system which appears during cell division.
The original vinca-alkaloids were derived from the dried leaves of
the Madagascan periwinkle (vinca rosea), but low yields of the active
compound limited the range of compounds available for study
(Johnson et al, 1960). Vinblastine and vincristine were the compounds
initially derived from the plant and both consisted of a cartharanthine
moiety linked to a vindoline ring. Subsequently, vindesine, a desacetyl
carboxyamid derivative of vinblastine, was developed.
Vinorelbine differs from the natural compounds by the presence
of an eight rather than nine member catharanine ring (Figure 1). It
is formulated as a light yellow amorphous powder.
Pharmacology
Vinorelbine is a mitotic spindle poison that impairs chromosomal
segregation during mitosis. It blocks cells at G2/M when present at
concentrations close to IC50: at higher concentrations there is produc-
tion of polyploidy (Pierre Fabre Medicament, 1993). Microtubules
(derived from polymers of tubulin) are the principal target of vinorel-
bine (Weisenberg, 1972). The chemical modification used to produce
vinorelbine allows opening of the eight-member catharanthine ring
with formation of covalent reversible bond with tubulin.
The relative contribution of different microtubule-associated
proteins in the production of tubulin vary between neural tissue
and proliferating cells and this has important functional implica-
tions. The capacity of vinorelbine to bind preferentially to mitotic
rather than axonal microtubules has been demonstrated and might
imply that neurotoxicity is less likely to be a problem than with the
other vinca-alkaloids (Paintrand and Pignot, 1983; Binet et al,
1989a). Assessment of the minimum concentration of drug
required to inhibit polymerization of the spindle, compared with
damage to the axonal microtubule, shows a ratio of 20:1
(Meninger et al, 1989). An additional advantage over other vinca-
alkaloids lies in the selective production of mitotic tubulin
paracrystallization which may point to enhanced cytotoxic action
(Binet et al, 1990).
Cytotoxicity has been demonstrated against a broad spectrum 
of human tumour cell lines (lung, breast, leukaemia, myeloma,
colon, melanoma, CNS). The IC50 lies between 1 and 50 nMol
(Ashizawa et al, 1993) (see Table 1).
Molecular mechanisms of action
Like other anti-microtubule agents vinorelbine is known to be a
promoter of apoptosis in cancer cells. The precise mechanisms by
which this process occurs are complex and many details are yet to
be elucidated. Disorganization of the microtubule structure has a
number of effects, including the induction of tumour suppressor
gene p53 and activation/inactivation of a number of protein
kinases involved in key signalling pathways, including p21
WAF1/CIP1 and Ras/Raf, PKC/PKA (Wang et al, 1999a). These
molecular changes result in phosphorylation and hence inactiva-
tion of the apoptosis inhibitor Bcl2 (Haldar et al, 1995). This in
turn results in a decrease in the formation of hetero-dimers
between Bcl2 and the pro-apoptotic gene BAX triggering the
process of apoptosis in the cell (Wang et al, 1999b).
Toxicology
The dose-limiting toxicity of vinorelbine is leucopenia. Transient
increase in SGOT and SGPT were noted in rats and dogs but not in
monkeys. In intact tectal planes from mouse embryos, vinorelbine,
vincristine and vinblastine were equipotent to induce a depolymeriza-
tion of mitotic microtubules, but vinorelbine was less active on axonal
microtubules than the other vinca-alkaloids (Binet et al, 1989b).
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Figure 1 Chemical structure of vinorelbine
Table 1 Cytotoxicity of vinorelbine against human tumour cell lines
Origin Number of lines studied IC50 in nMol
Leukaemia 2 1.59–9.38
NSCLC 8 1.74–19.8
SCLC 1 4.82
Colon 5 2.25–49.3
Breast 2 19.10 (400a)
CNS 2 2.06–4.60
Melanoma 5 1.6–24.00
Myeloma 6 0.00510–0.5
a Line with MDR phenotypeClinical pharmacology
The majority of data available for vinorelbine are based upon i.v.
administration of the drug. Initial phase I studies of vinorelbine
were performed in France, and the dose-limiting toxicity was
leucopenia – at a dose of 27.5 mg m–2 per week this was seen at
grade 3 in 14% of cycles (Mathe and Reizenstein, 1985). In addi-
tion, some peripheral neuropathy was noted. Subsequent dose-
finding studies, in which the dose was escalated from 30 mg m–2 in
5 mg increments, found the MTD to be 45 mg m–2 with the
neutrophil nadir to be at day 8–10. Despite 50% of the patients
sustaining grade 4 neutropenia or any grade 3 toxicity, none of 
the patients required hospitalization (Khayat et al, 1995). In
clinical practice, many studies have demonstrated excellent 
dose-intensity with little significant toxicity using a schedule of
25–30 mg m–2. i.v. Days 1 and 8 on a 21-day cycle.
Pharmacokinetics
The pharmacokinetic properties of vinorelbine have been well
defined with the development of radioimmunoassay methods
(Rahmani et al, 1984) and highly sensitive high-performance
liquid chromatographic (HPLC) assays using fluoresence (Debal
et al, 1992), ultraviolet (Jehl et al, 1990) or electrochemical detec-
tion (Van Belle et al, 1992). The pharmacokinetic properties of
intravenously administered vinorelbine can be described by a three
compartment model: after a dose of 30 mg m–2 i.v. a high initial
peak of 5 umol rapidly decays to about 1 nmol at 2 h. Distribution
in blood is rapid, with binding of 78% of the drug to platelets and
a further 13.5% to plasma proteins with only 1.7% left as free drug
in the first 2 h after administration. Subsequently, binding to
plasma proteins is in the order of 70–80%. The drug diffuses freely
into tissues showing a large volume of distribution and an elimina-
tion half-life of 40 h (Marquet et al, 1992).
Within 30 min of administration vinorelbine is highly concentrated
in bile, excretory organs (spleen, liver and kidney), lung, muscle and
heart in a range of experimental animals (Kobayashi et al, 1993). High
levels of vinorelbine are found in both normal lung and tumour tissue
and diffusion out of tumour tissue appears to be slow (Leveque et al,
1993). Brain and plasma levels are comparable in animal studies
(Kobayashi et al, 1993). In pregnant rats drug is seen to cross the
placenta and is detectable in the foetus (Van Belle et al, 1992).
There are some data available on the pharmacokinetics of the oral
preparation of the drug which is currently in clinical trial.
Vinorelbine has been evaluated as an oral preparation administered
as a gelatin-filled capsule (Lucas et al, 1992) in women with
advanced breast cancer (Spicer et al, 1994) and non-small cell lung
cancer (Vokes et al, 1994). Initial studies have shown bioavailability
for a soft liquid gelatin filled capsule to be 24% and for an unspeci-
fied formulation to be 40%; food did not appear to influence this
(Van Cantfort et al, 1989). Within a dose range of 50–180 mg, peak
plasma vinorelbine concentrations of 0.07–0.8 mg ml–1 were seen at
1–2 h after administration of drug (Van Cartfort et al, 1989). The
pharmacokinetic profile of orally administered vinorelbine is very
similar to that seen with the intravenous route. The exception to this
was an observed high clearance of 5.4 h–1kg–1 seen in nine patients
treated in the preliminary studies, and it was proposed that this was
due to first-pass hepatic metabolism (Cros et al, 1989).
Concentration–effect relationship
Data derived from testing against cell lines indicated that the IC50
was between 1 and 50 nmol which is a concentration range readily
attained by standard dosing at 30 mg m–2 which produces peak
plasma levels of 1 mmol, with levels of 1 nmol present at 72 h
(Levegue et al, 1992). Testing of the murine leukaemia model
P-388 demonstrated a steep dose-response curve with response
rates correlated to the total dose administered; these studies indi-
cated that dosing at weekly intervals would be predicted to provide
the most effective schedule (Cros et al, 1989).
Metabolism
The metabolism of vinorelbine is principally hepatic; only one
metabolite, deacetylvinorelbine, has been identified, the activity of
which is unknown (Jehl et al, 1991). Only 11% of the drug is
excreted via the renal route, the majority being eliminated through
faecal excretion (Bore et al, 1989). It is not known if the drug is
excreted in breast milk.
As the liver provides the main route for metabolism of the drug
it may follow that patients with hepatic impairment may show
increased toxicity with standard dosing but there are no available
data on this. Likewise the contribution of cytochrome P450
activity to vinorelbine metabolism has potential implications in
patients receiving other drugs metabolized by this route (Leveque
et al, 1992). There is no evidence that glucuronidization is
involved in the metabolism of vinorelbine.
Mode of use
The drug is administered by intravenous infusion into the side-port
of a running saline infusion over 6–10 min followed by a further
flush through to the vein to minimize vessel irritation. Care should
be taken to observe the infusion site as extravasation injuries may
be severe (Rittenberg et al, 1995). In view of the potential of
vinorelbine to produce painful phlebitis some centres administer it
by central venous catheter only.
There are no data on patients with severe hepatic impairment,
but it is recommended that the dose of vinorelbine be reduced in
hepatic impairment according to the bilirubin (see Table 2). There
is a lack of studies concerning renal insufficiency and administra-
tion of vinorelbine and the manufacturers advise caution before
initiating therapy in this group of patients. There is no evidence
that dose modifications are required in elderly patients with
normal hepatic and renal function.
CLINICAL EFFICACY
Vinorelbine as single agent therapy in non-small cell
lung cancer
So far over 15 trials with greater than 25 patients have been
published using vinorelbine as a single agent in non-small cell
lung cancer NSCLC and these are summarized in Table 3. The
overall response rate in the published trials is 23.6%. In a recently
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Table 2 Recommended dose modifications for vinorelbine in hepatic
impairment
Bilirubin Vinorelbine dose
≤2 mg dl–1 30 mg m–2
2.1–3 mg dl–1 15 mg m–2
> 3 mg dl–1 7.5 mg m–2published phase III trial, 161 elderly patients were randomized to
receive either vinorelbine or best supportive care; survival was
significantly improved with vinorelbine (32% vs 14% respectively
at 1 year, P = 0.003). In a quality of life analysis, functional scales
were consistently better for vinorelbine; patients treated with
vinorelbine scored better than controls for tumour-specific
symptoms including pain and dyspnoea, but worse for toxicity,
including constipation, nausea, hair-loss and neuropathy (The
Elderly Lung Cancer Vinorelbine Italian Study, 1999). Single-
agent vinorelbine seems a reasonable choice for administration in
the elderly in whom polychemotherapy is not deemed possible.
Vinorelbine in combination chemotherapy in NSCLC
Vinorelbine has also been extensively tested in combination in
NSCLC, most commonly with cisplatin. The published phase III
trials of cisplatin-navelbine are shown in Table 4. A multi-centre
European trial randomized patients to cisplatin (120 mg m–2 day 1
and day 29 and then 6-weekly) plus vinorelbine (30 mg m–2
weekly) or cisplatin and vindesine (3 mg m–2 weekly for 6 weeks
and then every 2 weeks) or vinorelbine alone. The cisplatin-
vinorelbine combination had a superior response-rate of 30%
compared to 19% for cisplatin-vindesine and 14% for vinorelbine
alone; 1-year survival rates were 35%, 27% and 30% respectively
(Le Chevalier et al, 1994). A pharmaco-economic analysis based
on this study concluded that the most effective regimen of vinorel-
bine and cisplatin added substantial benefit to vinorelbine alone or
another common regimen, vindesine/cisplatin, and a cost-effec-
tiveness within accepted limits for medical interventions (Smith
et al, 1995). A subsequent randomized phase III study from the
SWOG group randomized 415 patients with advanced non-small
cell lung cancer to receive either cisplatin 100 mg m–2 q28 or
cisplatin 100 mg m–2 and vinorelbine 25 mg m–2 weekly. There
was a statistically superior response-rate (12% vs 26%) and 1-year
survival (20% vs 36%) in favour of the combination arm (Wozinak
et al, 1998). Following this, studies have been performed
comparing the cisplatin-navelbine combination with other combi-
nation regimens.
Vinorelbine has also been studied in combination with other
drugs in non-small cell lung cancer. In a phase III study looking at
the importance of sequencing, two-drug combinations cisplatin-
vinorelbine performed well in advanced NSCLC compared to
epirubicin-ifosfamide with response-rates of 47% and 21% respec-
tively. Median overall survival was 13 months for the cisplatin-
vinorelbine combination compared to 7 months for the
epirubicin-ifosfamide combination (P = 0.03) (Colvcci et al, 1997).
Combined chemotherapy and radiotherapy is a common
approach in the treatment of NSCLC. In a phase II study of 33
patients, cisplatin-vinorelbine was used as the induction regimen in
patients with stage III-B disease prior to radical radiotherapy with
an objective response of 48%, leading the authors to conclude that
this is an effective regimen pre-radiotherapy (Felip et al, 1997).
The combination of carboplatin-vinorelbine would be an attrac-
tive alternative to cisplatin-navelbine, particularly in a more frail
population, because of the lack of necessity for pre-hydration.
However, one potential disadvantage of this regimen would be the
possibility of severe myelosupression given that this is the dose-
limiting toxicity of both agents. Two-dose escalation studies have
been performed looking at this combination. In the first, patients
received carboplatin at an AUC of 7 and then increasing doses of
vinorelbine up to 30 mg m–2. Patients were able to tolerate the
highest dose of vinorelbine but the majority required GCSF
support (Crawford et al, 1994). In a subsequent study from Italy
patients received a fixed dose of vinorelbine 25 mg m–2 in conjunc-
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Table 3 Single agent vinorelbine in treatment of NSCLC
Author Dose (mg m–2 per week) Points Overall response Median survival (weeks)
Depierre et al, 1991 30 78 29.4% 33
Rinaldi et al, 1994 20 27 7% –
Furuse et al, 1994 25 79 29.1% 40
Malzyner et al, 1991 30 36 33% 29.7
Crawford and O’Rourke, 1994 30 143 12% 30
Le Chevalier et al, 1994 30 206 14% 31
Gil Deza et al, 1996 30 73 42% 32.5
Furuse et al, 1994 25 103 31% 52.4
Veronesi et al, 1996 25–30 23 39.1% 38.7
Mattioli et al, 1997 30 15 20% –
Gridelli et al, 1998 30 42 24% 35
Tononi et al, 1997 25 25 12% 43
Table 4 Navelbine/cisplatinum in combination in NSCLC – Phase III trials
Author Drug combination Points Response Median survival (weeks)
Malzyner et al, 1991 N 30 mg m–2 weekly 39 36% –
Cis 100 mg m–2 q28
Depierre et al, 1991 N 30 mg m–2 weekly 116 48% 33
Cis 80 mg m–2 q21
Le Chevalier et al, 1994 N 30 mg m–2 weekly 206 30% 40
Cis 120 mg m–2 q42
Wozinak et al, 1998 N 25 mg m–2 weekly 206 26% 34
Cis 100 mg m–2 q28
Gil Deza et al, 1996 N 30 mg m–2 weekly 83 42% 41
Cis 100 mg m–2 q28
Gebbia et al, 1994 N 25 mg m–2 d1 + 8 50 38% –
Cis 100 mg–2 q28tion with carboplatin dose escalated from 300–400 mg m–2. At top
doses 19% of patients had grade III–IV neutropenia (Colleoni et
al, 1996). The response-rate for this combination is encouraging,
in one phase II study 77 patients with stage III and IV NSCLC
received carboplatin 350 mg m–2 D1 and navelbine
25 mg m–2 D1 and D8 q28: response-rate was 31% with no grade
IV toxicity observed (Santamaggio et al, 1996).
Paclitaxel is another relatively new drug that has attracted
interest in the treatment of NSCLC. It has been combined with
vinorelbine in a study of 18 patients with refractory metastatic
NSCLC, and the overall response-rate was 27% with the most
common side-effects being neutropenia and peripheral neuropathy
(Chang et al, 1996). Several groups have investigated the combi-
nation of ifosfamide and vinorelbine. A phase I study performed
by a US group found an overall response-rate of 40% with a 1-year
survival rate of 48%. The regimen was highly tolerable with some
patients continuing for 10 cycles (Masters et al, 1998). Cisplatin
has also been added into this combination in a phase II study
involving 76 untreated patients with advanced NSCLC with a
response-rate of 52% and with neutropenia being the main toxicity
necessitating the use of G-CSF in 27% of cases (Baldini et al,
1996). Similar response-rates were obtained using the triple
combination of cisplatin-gemcitabine-navelbine in chemo-naive
patients (Fiasci et al, 1997).
Vinorelbine as single agent therapy in metastatic breast
cancer
Vinorelbine has shown a level of single-agent activity equivalent
to that of many standard agents, including doxorubicin, epirubicin
and mitoxantrone (1992), with a response-rate for first-line treat-
ment of 40–60% (Fumoleau et al, 1993; Canobbio et al, 1989;
Vogel et al, 1999); published trials are detailed in Table 5. The
largest phase II trial on single-agent vinorelbine in metastatic
breast cancer treated 145 women with 30 mg m–2 weekly. The
overall response-rate was 41%; patients with skin, lymph node and
lung metastases seemed to do better than those with liver and bone
metastases. Previous anthracycline as adjuvant chemotherapy did
not appear to have any influence on response (Fumdeau et al,
1993). Clinical activity in the elderly shows similar response-rates
to those seen in younger patients, with no need to dose-reduce
(Canobbio et al, 1989). A recent study in which vinorelbine as
single-agent treatment was used as first-line therapy for metastatic
disease in patients over 60 showed a response of 38% with a
median duration of response of 9 months, and low toxicity (Vogel
et al, 1999). A phase II study of 183 patients comparing weekly
vinorelbine to 3-weekly melphalan showed an improved time to
progression (12 vs 8 months), an improved time to treatment
failure (12 vs 8 months) and improved overall survival (35.7% vs
21.7%) with vinorelbine (Jones et al, 1995). Economic assess-
ments of anti-cancer treatments are becoming increasingly impor-
tant to allow for targetting of resources. A recent cost–benefit
analysis of single agents in anthracycline pre-treated patients with
metastatic breast cancer compared vinorelbine, docetaxel and
paclitaxel. The authors concluded that vinorelbine provided
equivalent quality-adjusted disease-free survival with economic
advantage over the taxanes (Leung et al, 1999).
Vinorelbine in combination therapy for metastatic
breast cancer
Vinorelbine has principally been studied in combination with
anthracyclines. Published trials are summarized in Table 6. The
largest phase II study of vinorelbine/doxorubicin as first-line
therapy for metastatic disease was performed in the UK with 117
patients receiving both drugs at a dose of 25 mg m–2 on days 1 and
8 of a 21-day cycle; overall response-rate was 74% (Carmichael 
et al, 1997). In a randomized phase III study in 97 patients with
hormonal resistant advanced breast cancer, the vinorelbine/
doxorubicin combination achieved equivalent response-rates
(34%) to the FAC (5-FU, adriamycin, cyclophosphamide) regimen
(35%), and median duration of response was equivalent in the two
groups (Blajman et al, 1996). Vinorelbine has also been studied in
combination with epirubicin. In the largest published phase II
series, 52 patients received vinorelbine and epirubicin both at a
dose of 25 mg m–2 weekly; the overall response rate was 77% with
75% of patients alive at 2 years (Nistico et al, 1997).
Mitoxantrone has also been tested in combination with vinorel-
bine. In a phase III trial patients were randomized to receive
vinorelbine/mitoxantrone (MV) or a standard FAC/FEC) regimen.
The objective response-rates were similar (36% for MV vs 33%
for FAC/FEC). For patients who had received prior adjuvant
therapy those receiving the vinorelbine combination therapy had a
significantly better response rate (33% vs 13%; P = 0.025),
survival (20 vs 15 months; P = 0.01) and time to progression (8 vs
5 months; P = 0.0007) (Namer et al, 1997).
Vinorelbine has also been tested with other drugs in the treat-
ment of advanced breast cancer. The combination of 5-flurouracil
and vinorelbine in 63 patients treated in a phase II study in France
achieved a response rate of 64% with a median survival of 100
weeks (Dieras et al, 1996). Pre-clinical data suggesting synergy
between vinorelbine and the taxanes have been confirmed in a
phase II study of a combination of vinorelbine/paclitaxel showing
a response-rate of 60% (Romerso et al, 1998). The combination of
vinorelbine and paclitaxel appears particularly active. In a single-
institution study from the USA, 32 patients with anthracycline pre-
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Table 5 Single agent vinorelbine in treatment of metastatic breast cancer
Author Dose (mg m–2) per week Points Overall response Median survival (weeks)
Canobbio et al, 1989 30 19 60% –
Fumoleau et al, 1993 30 145 41% 78
Garcia-Conde et al, 1994 30 50 50% 65
Romero et al, 1994 30 44 41% –
Weber et al, 1995 30 65 40% 67
Bruno et al, 1995 30 63 44% 50
Twelves et al, 1994 25 34 50% 41
Terenziani et al, 1996 30 27 59% 82treated metastatic breast cancer received infusional paclitaxel and
weekly vinorelbine. Doses of both drugs were escalated according
to liver function and all patients received scheduled GCSF
support. Overall the response-rate was 50% with 22% of patients
sustaining a complete response (Ellis et al, 1999).
Finally, consideration is now being given to the use of vinorel-
bine combinations in neoadjuvant and adjuvant chemotherapy. The
French Oncology Group treated 104 patients with primary breast
cancer with induction chemotherapy with navelbine/mitoxantrone.
Overall response-rate was 45% with a 7% complete response. In
total 64% patients were subsequently able to undergo conservative
surgery (Adenis et al, 1996). Neutropaenia was the main toxicity
with 83% of patients registering grade 3 neutropaenia. In summary,
vinorelbine shows single-agent response-rates comparable to stan-
dard drugs in metastatic breast cancer and with low toxicity. In
combination chemotherapy randomized trials containing the drug
have shown equivalent or superior response-rates to standard
combinations, again with less toxicity.
Other tumours
Vinorelbine has had some assessment in other malignancies. The
combination of carboplatin-vinorelbine in small cell lung cancer
has shown a response-rate of 74% (Gridelli et al, 1998) and is
currently being investigated in the UK as a treatment for those
patients with small cell lung cancer with a poor prognosis. In plat-
inum-resistant ovarian carcinoma one study found single-agent
activity of the drug to be 30% (Gershenson et al, 1998). Preliminary
studies of vinorelbine in patients with cervical carcinoma recurring
after radiotherapy found an overall response rate of 21% (Morris et
al, 1998). It has been assessed in a range of B-cell malignancies as
palliative treatment for extensively pre-treated patients. In patients
with relapsed Hodgkin’s disease 50% responded to vinorelbine
with a median duration of remission of 6 months (Devizzi et al,
1994). In patients with relapsed multiple myeloma 61% of patients
achieved stabilization of their disease with 16% achieving an objec-
tive response (Harousseau et al, 1997).
Toxicity
Vinorelbine is in general a well-tolerated cytotoxic agent but it
does have some important toxicities.
Haematological
The main haematological toxicity seen with vinorelbine is
neutropaenia and this is dose-limiting. Grade 3–4 neutropenia has
been observed in 14–52% of patients treated with weekly intra-
venous vinorelbine; it is reversible, with a usual duration of 7–14
days, and is not cumulative, however dose adjustments have been
required in up to 70% of patients (Cvittovic and Izzo, 1992).
Thrombocytopaenia is rare during therapy with vinorelbine.
Neurological
The vinca-alkaloids are recognized as causing neurological toxi-
city. Neurotoxic effects of vinorelbine include decreased deep-
tendon reflexes, constipation, parasthesiae, myalgia, jaw pain and
paralytic ileus. Peripheral neuropathy has been reported in up to
30% of patients receiving vinorelbine but this was severe, i.e.
grade III or above, in only 1% (Navelbine Product Information).
This is less than the other vinca-alkaloids; for example the
incidence of peripheral neuropathy with vincristine is in the 
order of 57% (Cvittovic and Izzo, 1992).
Gastro intestinal effects
Severe nausea and vomiting are relatively infrequent with vinorel-
bine. Grade 3 or 4 toxicity has been reported in only 1–3% of patients
(Cvittovic and Izzo, 1992; Dubos et al, 1991). Constipation and para-
lytic ileus have also been reported (Cvittovic and Izzo, 1992).
Venous access pain
Grade 3 or 4 cutaneous or venous reactions, e.g. pain on injection,
venous pain and thrombophlebitis, have occurred in 5–10% of
patients receiving vinorelbine (Besenval et al, 1991). This can to
some extent be prevented by adequate flushing through of the vein
with normal saline following injection of the drug. At the Royal
Marsden Hospital these problems have been minimized by using a
heat pad on the distal vein. In addition, patients receive a saline
flush before and after the injection which is given over 6 min (Lisa
Dougherty – CNS IV Services, personal communication).
Alopecia
This affects only 10% of patients treated with vinorelbine and is of
minor severity. Very few patients experience total hair loss or
require a wig.
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Table 6 Navelbine/anthracycline combinations in metastatic breast cancer
Author Drug combination Points Overall response Median survival (weeks)
Spielmann et al, 1994 N 25 mg m–2 d1+8 87 74% 118
Dox 50 mg m–2 q21
Hochster et al, 1994 N 25 mg m–2 d1+8 62 57% –
Dox 50 mg m–2 q21
Blajman et al, 1996 N 25 mg m–2 d1+8 86 76% 82
Dox 50 mg m–2 q21
Vorobiof et al, 1997 N 25 mg m–2 d1+8 24 54% –
Dox 50 mg m–2 q21
Arca et al, 1998 N 25 mg m–2 d1+8 70 68% 68
Dox 50 mg m–2 q21
Carmichael et al, 1997 N 25 mg m–2 d1+8 117 74% –
Dox 25 mg m–2 d1+8
Chadjaa et al, 1993 N 25 mg m–2 d1+8 30 60% 36
Epi 60 mg m–2 q21
Nistico et al, 1997 N 25 mg m–2/week 52 77% 43
Epi 25 mg m–2 weeklyCardiovascular effects
Acute myocardial infarction has been reported following the
administration of vinorelbine (Dubos et al, 1991).
CONCLUSION
Vinorelbine is an active new vinca-alkaloid with a different spec-
trum of activity from parent compounds. In particular it has high
activity in breast cancer where it is one of the most active agents
currently available, and it has useful activity in non-small cell lung
cancer. Its relatively low incidence of side-effects makes it a useful
new addition to the treatment of breast cancer and non-small cell
lung cancer, and further combination studies are warranted.
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